2021
Mobility and Muscle Strength in Recipients of Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from Sickle Transplant Evaluation of Longterm and Late Effects Registry (STELLaR)
Veludhandi A, John T, Bakshi N, Arnold S, Bhatia M, Lane P, Meacham L, Khemani K, Chaudhury S, Olowoselu F, Kasow K, Hsieh M, Abraham A, Guilcher G, Krishnamurti L. Mobility and Muscle Strength in Recipients of Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from Sickle Transplant Evaluation of Longterm and Late Effects Registry (STELLaR). Blood 2021, 138: 3030. DOI: 10.1182/blood-2021-152383.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseMuscle strengthCGVHD symptomsHCT recipientsCell transplantationPhysical fitnessYoung adultsPost-HCTChronic graftHost diseaseMarrow transplantationGrip strengthTUG scoresRisk factorsCell diseasePathophysiology of SCDJournal of ParenteralCardiometabolic risk factorsLong-term survivorsHand-grip dynamometryHand grip strengthCross-sectional studyHandgrip strength testYears of age
2020
Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy
Thompson A, Walters M, Mapara M, Kwiatkowski J, Krishnamurti L, Aygun B, Kasow K, Rifkin-Zenenberg S, Schmidt M, DelCarpini J, Pierciey F, Miller A, Gallagher M, Chen R, Goyal S, Kanter J, Tisdale J. Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. Blood 2020, 136: 16-17. DOI: 10.1182/blood-2020-134940.Peer-Reviewed Original ResearchAcute chest syndromeVaso-occlusive crisisSickle cell diseaseVaso-occlusive eventsPain intensity scoresGroup C patientsAdverse eventsPain intensityBluebird BioC patientsLast visitBusulfan conditioningHemolysis markersTotal HbIntensity scoresAcute vaso-occlusive painBackground Sickle cell diseasePathophysiology of SCDVaso-occlusive pain crisesPopulation normsPatient-reported pain intensityAdvisory CommitteeGene therapy×109/LAbnormal sickle hemoglobin